CSPC Pharmaceutical’s SYS6006 mRNA Vaccine Shows Strong Safety and Efficacy in Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA...
CSPC Pharmaceutical
CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...
CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...
CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for...
Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta
The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...
CSPC Pharmaceutical’s Albumin-Bound Docetaxel Receives Orphan Drug Designation for Gastric Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received an orphan drug...
CSPC Pharmaceutical’s JMT103 Anti-RANKL Antibody Prioritized for CDE Review
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its market filing for JMT103, an...
CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies
The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC...